ArticleBMC microbiology2025
Clinical evaluation of an in-house Xpert Lysate-based Method combined with MALDI-TOF MS for the rapid identification of positive blood cultures.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical application of MALDI-TOF MS for direct and rapid pathogen identification: a comprehensive review focusing on bloodstream infections and sterile body fluids.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundIn clinical practice, bloodstream infections (BSIs) can lead to a very high mortality rate. Rapid identification (ID) of the pathogenic bacteria in positive blood cultures (PBCs) can guide the clinical implementation of effective antibiotic treatment in advance, thereby helping to reduce the mortality rate.
methodsUsing the Conventional Culture Method results as criteria, we evaluated the effectiveness of our newly developed in-house method, the Xpert Lysate-based Method, for rapidly identifying pathogens in PBCs across four hospitals.
resultsA total of 629 monomicrobial PBCs were investigated. The Xpert Lysate-based Method correctly identified 96.18% of PBCs at the species level and 97.30% at the genus level. When the confidence scores of MALDI-TOF MS were ≥ 2.000, ≥ 1.700, and ≥ 1.500, the percentages of correctly identified PBCs at the species level were 67.47%, 94.24%, and 98.88%, respectively. When the score threshold of species-level ID was set to 1.500, the rates reached 98.25% for Gram-positives (GPs), 93.54% for Gram-negatives (GNs), 70.00% for anaerobes, and 94.74% for fungi, respectively. The median confidence score of ≥ 2.000 indicated high certainty in identifying common BSI pathogens. Additionally, one of the microbial species was correctly identified in 10 out of 11 PBCs with polymicrobial growth. The entire operation process took an average of 10 min of hands-on time and 15 to 20 min for time-to-result.
conclusionThe method of directly identifying microbial pellets using MALDI-TOF MS, extracted via the Xpert Lysate-based Method we developed, is non-inferior to the conventional Culture Method in terms of ID performance. Meanwhile, it is easy to operate and more time-efficient, making it suitable for routine workflow in the rapid etiological ID of PBCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.